Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
第一作者机构:[1]Army Med Univ, Dept Resp Med, Daping Hosp, Chongqing, Peoples R China[2]Shanghai Jiao Tong Univ, Dept Pulm, Shanghai Chest Hosp, Shanghai, Peoples R China[3]Shanghai Jiao Tong Univ, Dept Pulm Med, Shanghai Chest Hosp, Shanghai, Peoples R China[4]Peoples Hosp Henan Prov, Dept Pulm Med, Zhengzhou, Henan, Peoples R China[5]Army Med Univ, Anqiao Hosp, Inst Resp Dis, Chongqing, Peoples R China[6]Third Mil Univ, Affiliated Hosp 1, Chongqing, Peoples R China[7]Army Med Univ, Anqiao Hosp, Inst Canc, Chongqing, Peoples R China[8]Shanxi Prov Peoples Hosp, Dept Med Oncol, Xian, Shaanxi, Peoples R China[9]Chongqing Three Gorges Cent Hosp, Ctr Canc, Chongqing, Peoples R China[10]Chengdu Mil Command, Depantment Respirat, Gen Hosp, Chengdu, Sichuan, Peoples R China[11]Army Med Univ, Dept Pathol, Daping Hosp, Chongqing, Peoples R China[12]Fuling Ctr Hosp, Dept Oncol, Chongqing, Peoples R China[13]Army Med Univ, Dept Cardiothorac Surg, Southwest Hosp, Chongqing, Peoples R China[14]Chongqing Med Univ, Affiliated Hosp 2, Ctr Canc, Chongqing, Peoples R China[15]3D Med Inc, Dept Med, Shanghai, Peoples R China
推荐引用方式(GB/T 7714):
He Yong,Li Li,Jiang Liyan,et al.Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial.[J].JOURNAL OF CLINICAL ONCOLOGY.2019,37(15):
APA:
He, Yong,Li, Li,Jiang, Liyan,Wang, Yubo,Zhao, Yizhuo...&Gao, Chan.(2019).Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial..JOURNAL OF CLINICAL ONCOLOGY,37,(15)
MLA:
He, Yong,et al."Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial.".JOURNAL OF CLINICAL ONCOLOGY 37..15(2019)